-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, affected by the changes in the pharmaceutical industry, in order to respond to more and more market challenges and accelerate the development and commercialization of innovative drugs, the cooperation between pharmaceutical companies is becoming more and more frequent
.
Among them, the more leading companies, the more they like to join forces
.
It is reported that there has been a wave of cooperation among large multinational pharmaceutical companies recently
.
On May 4, Genesis Therapeutics announced that it has entered into a partnership with Eli Lilly to use Genesis' artificial intelligence (AI) drug discovery platform to discover innovative treatments for up to 5 targets across multiple therapeutic areas
.
According to public information, Genesis' molecular AI platform combines 3D structure-aware deep neural networks, novel molecular simulation methods, and a greatly scalable molecular generation engine
.
The company's technology is particularly well suited for targeting previously undruggable or data-poor targets
.
Under the agreement, scientists from Genesis and Eli Lilly will jointly use Genesis' AI drug discovery platform to develop potential "first-in-class" and "best-in-class" drug candidates against three targets
.
Genesis will receive up to $670 million in up-front and milestone payments, while Lilly has the option to add two additional targets
.
On the same day, Amphista Therapeutics announced that it has reached R&D cooperation with Bristol-Myers Squibb and Merck respectively to develop a new generation of protein degradation therapy based on its protein degradation agent discovery platform
.
Together, the two companies will bring in $2.
3 billion in revenue for the British biotech company
.
Specifically, in the collaboration with Merck, the two companies will develop small-molecule protein degraders for three targets in oncology and immunology
.
Amphista will receive $44 million in up-front cash and the potential for $1 billion in milestone payments
.
In the partnership with Bristol-Myers Squibb, which will collaborate on the discovery and development of small molecule protein degraders, Amphista received an upfront payment of $30 million and is eligible to receive a milestone payment of $1.
25 billion
.
There are already several protein degradation therapies in BMS' own pipeline, among which CC-92480 has entered clinical phase
I.
On May 3, Gilead and Dragonfly Therapeutics also jointly announced that the two parties have reached a research and development cooperation to jointly advance a series of Dragonfly immunotherapies based on innovative natural killer (NK) cell adaptor proteins for oncology and inflammatory indications
.
NK cell adaptor proteins represent an innovative mechanism of action with potential to treat a broad range of cancer types
.
According to the agreement, Gilead will acquire the development rights of the immunotherapy DF7001, which targets 5T4, and obtain the option to acquire the research and development rights of other candidate therapies based on Dragonfly's TriNKET technology platform
.
Gilead will pay $300 million upfront, and Dragonfly is also eligible for multiple milestone payments
.
In addition to the above-mentioned companies, domestic and foreign pharmaceutical companies such as AstraZeneca, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilicon, Biocytos, and BeiGene have also announced new and diversified cooperation announcements since the beginning of this year.
.
Analysts believe that this is mainly due to changes in the pharmaceutical industry
.
In order to respond to more and more market challenges, accelerate the research and development of new drugs, develop combination therapies, and enhance competitiveness, a large number of domestic and foreign pharmaceutical companies will join forces to achieve complementary advantages, better promote research and development, and accelerate the process of product commercialization
.
In the future, this will also benefit more patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, the more leading companies, the more they like to join forces
.
It is reported that there has been a wave of cooperation among large multinational pharmaceutical companies recently
.
On May 4, Genesis Therapeutics announced that it has entered into a partnership with Eli Lilly to use Genesis' artificial intelligence (AI) drug discovery platform to discover innovative treatments for up to 5 targets across multiple therapeutic areas
.
According to public information, Genesis' molecular AI platform combines 3D structure-aware deep neural networks, novel molecular simulation methods, and a greatly scalable molecular generation engine
.
The company's technology is particularly well suited for targeting previously undruggable or data-poor targets
.
Under the agreement, scientists from Genesis and Eli Lilly will jointly use Genesis' AI drug discovery platform to develop potential "first-in-class" and "best-in-class" drug candidates against three targets
.
Genesis will receive up to $670 million in up-front and milestone payments, while Lilly has the option to add two additional targets
.
On the same day, Amphista Therapeutics announced that it has reached R&D cooperation with Bristol-Myers Squibb and Merck respectively to develop a new generation of protein degradation therapy based on its protein degradation agent discovery platform
.
Together, the two companies will bring in $2.
3 billion in revenue for the British biotech company
.
Specifically, in the collaboration with Merck, the two companies will develop small-molecule protein degraders for three targets in oncology and immunology
.
Amphista will receive $44 million in up-front cash and the potential for $1 billion in milestone payments
.
In the partnership with Bristol-Myers Squibb, which will collaborate on the discovery and development of small molecule protein degraders, Amphista received an upfront payment of $30 million and is eligible to receive a milestone payment of $1.
25 billion
.
There are already several protein degradation therapies in BMS' own pipeline, among which CC-92480 has entered clinical phase
I.
On May 3, Gilead and Dragonfly Therapeutics also jointly announced that the two parties have reached a research and development cooperation to jointly advance a series of Dragonfly immunotherapies based on innovative natural killer (NK) cell adaptor proteins for oncology and inflammatory indications
.
NK cell adaptor proteins represent an innovative mechanism of action with potential to treat a broad range of cancer types
.
According to the agreement, Gilead will acquire the development rights of the immunotherapy DF7001, which targets 5T4, and obtain the option to acquire the research and development rights of other candidate therapies based on Dragonfly's TriNKET technology platform
.
Gilead will pay $300 million upfront, and Dragonfly is also eligible for multiple milestone payments
.
In addition to the above-mentioned companies, domestic and foreign pharmaceutical companies such as AstraZeneca, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilicon, Biocytos, and BeiGene have also announced new and diversified cooperation announcements since the beginning of this year.
.
Analysts believe that this is mainly due to changes in the pharmaceutical industry
.
In order to respond to more and more market challenges, accelerate the research and development of new drugs, develop combination therapies, and enhance competitiveness, a large number of domestic and foreign pharmaceutical companies will join forces to achieve complementary advantages, better promote research and development, and accelerate the process of product commercialization
.
In the future, this will also benefit more patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
